The first Phase III trials of an inactivated vaccine for COVID-19 in the United Arab Emirates are among the largest in the world in volunteer recruitment having reached 31,000 vaccinated volunteers from more than 120 nationalities in only six weeks.
Indonesia, home to approximately 300 million, is among the first to benefit from the ongoing UAE-China Phase III anti-COVID-19 candidate vaccine clinical trial in Abu Dhabi and Sharjah.
A new candidate vaccine against the mutating virulent SARS-CoV2, which has at least four identified dominant variants, is on its way to its Phase III clinical trial targetting 4,000 adult volunteer-participants from various parts of the globe.
Abu Dhabi is currently hosting the final phases of the clinical trials of two key vaccines that were announced earlier, the Chinese vaccine, 'Sinopharm CNPG,' and the Russian 'Sputnik V vaccine.'
"Since it was tried on patients with different variants of COVID-19, we expect it to be effective on Omicron as on other variants," Professor Iqbal Chaudhry, director of the International Centre for Chemical and Biological Science (ICCBS) where trials were conducted, told reporters.